Introduction to the special issue: the two sides of hemp: medical and industrial | Journal of Cannabis Research
The regulatory landscape surrounding hemp is evolving rapidly, with changes in laws and regulations opening up new opportunities for research, cultivation, and commercialization. As governments around the world recognize the medical, economic and environmental potential of hemp, there is a trend towards legalization and deregulation of hemp cultivation and processing. Some countries define hemp as a cannabis plant containing less than a specified concentration of THC (e.g., 0.3%, 0.5%) regardless of its botanical classification. Clear and consistent regulations are essential to support the growth of the hemp industry while ensuring consumer safety and compliance with the law.
Overall, the future of the hemp industry looks promising, with opportunities for innovation and sustainable development across a wide range of sectors. As scientific understanding and public acceptance of hemp continue to grow, the potential of hemp becomes increasingly apparent. Realization of this potential will depend on continued research, innovation, and collaboration across different sectors.
This special issue collates manuscripts on the topic of hemp plant science, genetics, chemistry, regulation, and medical and industrial uses. Encompassing contributions from a variety of disciplines, it represents the type of scholarship conducted to-date in this growing field.
The following section provides a brief outline of the content of each manuscript and its main contribution.
Henry et al. (2020) present a targeted genetic assay and algorithms related to sub-genus classification in cannabis including hemp sub-classes. Cannabis accessions were investigated using 23 polymorphic SNP (Single Nucleotide Polymorphism) markers associated with key traits including cannabinoid and terpenoid expression, and fiber and resin production. The results offers insight into cannabis population structure, phylogenetic relationship, population genetics and correlation to secondary metabolite concentrations.
Berthold et al. (2020) describe an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method, with a short run time of 6 min, for the quantification of twelve cannabinoids in hemp samples. This method was applied in a trial regulatory study, and the results revealed that the sampling and analyses methods may influence the detected cannabinoid concentrations, and hence the legality of a hemp crop.
Huang et al. (2023) characterized the phytochemical profile of industrial hemp roots, and studied the anti-inflammatory activities of hemp roots extract. Six cannabinoids, and 26 non-cannabinoid compounds were identified in the root extracts; and cannabinoids as well as seven non-cannabinoid compounds from root extracts exerted promising anti-inflammatory effects.
Torres et al. (2022) investigated methodologies for high-throughput sex identification genotyping in cannabis plants, including hemp, using both novel and literature marker sets. They demonstrated a robust high-throughput duplex TaqMan qPCR assay for identification of male-specific genomic signatures, using a novel MADC2 (male-associated DNA from Cannabis) qPCR probe. The viability of using nearby regions to MADC2 with novel primers were demonstrated as alternative assays.
Filer (2020) reviewed the role of Minnesota wild hemp in early cannabinoid discovery. Studies conducted in the early 1940’s identified that Minnesota wild hemp served a critical role not only as a crucial fiber plant during World War II but also as a key botanical source for cannabinoid chemistry discoveries.
Falkner et al. (2023) performed a content analysis to analyze terms and definitions used by tribal and state hemp producers, the USDA hemp producer license, and the 2014 state pilot plans. The results identified discrepancies among different hemp production plans, that were intensified by extending the 2014 Farm Bill language into the 2018 Farm Bill timeframe.
Burton et al. (2022) review and discusses opportunities for designing a supply chain for industrial hemp, focused on hemp seed and its components for food applications. Market opportunities for industrial hemp products are discussed, as well as growth, harvest, storage conditions, and nutritional properties of hemp seed required to produce value-added food ingredients.
Johnson et al. (2023) performed a laboratory and market analysis to evaluate the adherence of hemp products to legal regulations in the US. The results revealed that some hemp products are inaccurately labeled andcontain higher levels of THC than would be allowed legally for recreational (“adult”) use. This raises consumer safety concerns involving consuming intoxicating products.
Johnson et al. (2022) analyzed the CBD content in commercial hemp-derived CBD products available in Central Kentucky from both online and local retailers. The results demonstrated that CBD content in over-the-counter CBD products is often inconsistent with the label claims.
Vasudevan and Stahl (2020) evaluated the efficiency of cannabinoids (CBG/CBD) infused mouthwash products against dental plaque bacteria. The cannabinoids infused products showed a similar bactericidal efficacy as that of chlorhexidine 0.2%, and no significant difference was observed between CBD- and CBG-mouthwash. These in vitro results demonstrate the potential of cannabinoids for developing efficient and safer mouthwash products that do not contain fluoride and alcohol.
Zadik-Weiss et al. (2020) conducted a literature review to evaluate the potential of domestic cats as a spontaneous model for Alzheimer’s disease. In line with the One-Health concept, feline cognitive dysfunction was identified as a promising model for human Alzheimer’s disease. The authors suggest that performing a clinical trial in aging domestic cats, for researching the benefits of CBD (often derived from hemp) for both conditions, can promote the treatment of these two conditions in both humans and pets.
Mazza (2021) assessed the efficacy and adverse events of short- and long-term medical cannabis treatment for fibromyalgia syndrome, in patients resistant to conventional therapy, which were treated with medical cannabis of various THC and CBD contents. The results suggest medical cannabis as an alternative treatment for patients unresponsive to conventional therapy. However, its application may be limited by the incidence of nonserious adverse events.
Trac et al. (2021) explored the literature related to the potential anticancer therapeutic activity of the cannabinoid-quinone HU-331, in purified systems, cancer cell lines, and animal models. The available studies indicates that HU-331 has promising anticancer properties, and support its further evaluation for the treatment of cancer and possibly other diseases.
Bilge and Ekici (2021) report on a 2-year study with CBD-enriched cannabis for the treatment of autism, and review the latest studies regarding CBD treatment in autism spectrum disorder. The most substantial improvements were found in behavioral problems, described in 20–70% of the patients under the low doses of CBD-enriched cannabis used (an average daily dosage of 0.7 mg/kg/day CBD, with no significant side effects.
Hall et al. (2023) were first to assess the tolerability of CBD in former elite athletes, a population that is susceptible to chronic pain duo to disabling injuries, and also highly trained to assess medication tolerability concerns. Topical CBD administration was well tolerated by this population and resulted in only minor adverse effects, and there was a significant improvement in pain levels and pain-related disability.
Wurz et al. (2022) evaluated cannabinoid kinetics and impairment patterns associated with the use of Δ8-THC. Cannabinoid kinetic patterns after Δ8-THC vaporizing were similar to those observed for ∆9-THC; and hemp-derived Δ8-THC and Δ9-THC displayed similar impairment profiles, suggesting that use of Δ8-THC products may carry the same risks as Δ9-THC products.
Wyse and Luria (2021) reviewed intellectual property rights (IPR) data for medical cannabis, including hemp, with the aim of advancing applied cannabis research by providing insights into medical cannabis patenting. The results present characteristics of the intellectual property landscape of the medical cannabis field, with the IPR data shown to be distributed along the entire medical cannabis supply chain, following the upstream–midstream–downstream paradigm.
Stats et al. (2023) evaluated the causes for the collapse of the CBD-hemp cultivation industry in Yuma County, Arizona, USA. Major factors were identified for this trend: lack of knowledge on the life cycle of the hemp plant, noncompliance with THC limits, poor seed sources and inconsistent genetics, and susceptibility to diseases such as beet curly top virus, crown root rot, and Pythium.
Sommano et al. (2022) evaluated the recent guidelines for receiving a cannabis production license in Thailand, including hemp, and demonstrated that the announced law is in-line with regulations in many countries in terms of prevention of misuse and security. The authors recommend that the regulation in Thailand should be revisited to promote cannabis as an economic crop, and for tighter control and prevention of misuse.
Quansah Amissah (2022) examined local cannabis production, industrial hemp facilities, and the potential benefits of industrial and medical hemp in Ghana. Based on the availability of resources, and the potential benefits of hemp-based drugs to Ghanaians, the most promising and feasible option for the government to invest in was identified to be exploitation of medicinal hemp.
Quansah Amissah (2023) focuses on Ghana’s potential to establish a hemp industry, based on its suitable climate, available agricultural resources, and the policies that support enhancement of the agricultural sector. They concluded that development of a Hemp industry could drive economic growth, create job opportunities and promote sustainable development in Ghana.
